Breaks Categories: News

FridayMar 03, 2023 2:53 pm

BioMedNewsBreaks – BioRestorative Therapies Inc. (NASDAQ: BRTX) Receives Notice of Third US Patent Related to ThermoStem IP

BioRestorative Therapies (NASDAQ: BRTX), a clinical-stage company focused on stem cell-based therapies, has received a notice of allowance for the patent application relating to its metabolic ThermoStem(R) program. The notice, dated Feb. 24, 2023, came from the United States Patent and Trademark Office. This marks the third patent approved relating to this specific group of intellectual property, the company noted; the new patent covers three-dimensional scaffolds and brown adipocytes that have been derived from human brown adipose-derived stem cells, which have exhibited potential to be a valuable therapeutic tool for treating a range of metabolic disorders. The company also indicated that it…

Continue Reading

FridayMar 03, 2023 11:33 am

BioMedNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Retains Top Banking Firm to Support Growth, Revenue-Generating Strategy

Aditxt Inc. (NASDAQ: ADTX), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, announced that it is working with Riverside Management Group LLC, a merchant banking firm providing investment banking advisory services; RMG will be supporting Aditxt’s strategic growth and revenue generating plans for its subsidiary Pearsanta Inc., as well as other Aditxt programs. The company noted that Pearsanta was formed to accelerate the growth of AditxtScore(TM) and focused on expanding the market through new offerings and customer acquisitions. A AditxtScore is the company’s exclusive platform designed offer a personalized profile of the…

Continue Reading

FridayMar 03, 2023 10:25 am

BioMedNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) CEO Joins Chopra Foundation Founder, Other Experts in Psychedelics Discussions

Cybin (NEO: CYBN) (NYSE American: CYBN) CEO Doug Drysdale and Chopra Foundation founder Deepak Chopra will be participating together on a panel at the upcoming South by Southwest(R) (SXSW) Conference; the title of the panel is “Open Minds: Innovations in Consciousness, Psychedelics & Mental Health.” The SXSW event is slated for March 10–19, 2023, and will be held in Austin, Texas. The panel that Drysdale and Chopra are participating on is scheduled for March 12 at 11:30 a.m. CT. According to the announcement, other panel members include Cristie Strongman MA, EdM, a psychotherapist at the Multidisciplinary Association for Psychedelic Studies (MAPS),…

Continue Reading

ThursdayMar 02, 2023 1:09 pm

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Schedules Q4 and FY 2022 Results Call

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (“VECG”) platform for heart attack detection anytime, anywhere, today announced its plans to host a conference call to discuss its results for the fourth quarter and full fiscal year ended Dec. 31, 2022. The call is scheduled to start at 4:30 p.m. Eastern Time on Thursday, March 16, 2023. HeartBeam CEO and Founder Branislav Vajdic, PhD, President Robert Eno, CFO Richard Brounstein, and CBO Jon Hunt, PhD, will review the results and discuss recent announcements, ongoing initiatives and key 2023 milestones. Interested parties should…

Continue Reading

WednesdayMar 01, 2023 12:40 pm

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) News Discussed in Latest InvestmentPitch Media Video

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, was featured in a recent InvestmentPitch Media video release. The video focused on FSD Pharma’s recent announcement that entrepreneur Kevin Harrington was joining its advisory board. According to the announcement, Harrington, the inventor of the modern infomercial format and one of the original “sharks” on the hit ABC show “Shark Tank,” will help expand the reach of the company and its brands. Company officials noted that, with Harrington’s…

Continue Reading

TuesdayFeb 28, 2023 11:37 am

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Expands Advisory Board to Welcome Original ‘Shark’ and Visionary Kevin Harrington

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, today announced that iconic entrepreneur Kevin Harrington has joined its advisory board. Harrington is world renowned as the inventor of the informercial, pioneer of the “As Seen on TV” brand, and one of the original “sharks” on the hit ABC show “Shark Tank.” He has launched more than 20 businesses as part of a career that has introduced 1,000+ products generating over $6 billion in global sales. “Kevin…

Continue Reading

TuesdayFeb 28, 2023 11:30 am

BioMedNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Progress Updates on Two Clinical Development Programs

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), is reporting on its two lead clinical development programs: CYB003, a proprietary deuterated psilocybin analog for the potential treatment of major depressive disorder (“MDD”), and CYB004, a proprietary deuterated N,N-dimethyltryptamine molecule being developed for the potential treatment of generalized anxiety disorder (“GAD”). According to the announcement, interim data from the CYB003 phase 1/2a study exhibited rapid and short-acting effects; strong psychedelic effects at low doses; and a positive safety and tolerability profile. The company anticipates having top-line efficacy data by late Q3 2023. In addition, initial…

Continue Reading

ThursdayFeb 23, 2023 10:05 am

BioMedNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Plan to Streamline Efforts, Maximize Efficiency, Focus on Clinical Trials

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has announced a strategic plan designed to streamline efforts, maximize operating efficiency and focus on critical clinical trials, including near-term, mid-term and long-term milestones. A part of that plan was the release of an estimated 15% of Cybin’s workforce, including those in roles that were identified as not a clinical priority or not directly involved with any clinical trial initiatives. This move alone is expected to generate cost savings by reducing operating expenses. The announcement noted that with the anticipated cost savings from the overall streamlining…

Continue Reading

TuesdayFeb 21, 2023 2:42 pm

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) CEO Featured in Recent “Authority” Magazine Interview

HeartBeam (NASDAQ: BEAT) CEO and founder Branislav Vajdic, PhD, is featured in a recent interview with David Leichner that was published in “Authority” magazine. The interview was one of a series of interviews with leaders of tech companies. The series, called “Technology Making an Important Positive Social Impact,” spotlights companies working on making monumental positive changes to society, health, and the environment. In the interview, Vajdic talked about his journey to HeartBeam, including the first half of his career, which was spent as a chip designer with Intel Corporation; Vajdic was involved in the design of the first Flash memory,…

Continue Reading

TuesdayFeb 21, 2023 11:19 am

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) to Interact with Leaders Pushing Boundaries of MS Research at Upcoming Forum

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders. The company today announced upcoming participation in the Americas Committee for Treatment and Research in Multiple Sclerosis (“ACTRIMS”) 2023 Forum taking place from Feb. 23-25 in San Diego, California, at the Marriott Marquis San Diego Marina. Founded in 1995, ACTRIMS is comprised exclusively of multiple sclerosis (“MS”) researchers and clinicians. “ACTRIMS provides us with an opportunity to interact with an esteemed community of leaders pushing the boundaries…

Continue Reading